Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.

Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.

Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.

Abstract: The present invention relates to subtilase variants and subtilases with an altered immunogenicity, particularly subtilase variants and subtilases with a reduced allergenecity. Furthermore, the invention relates to expression of said subtilase variants and subtilases and to their use, such as in detergents and oral care products.

Abstract: The present invention relates to a method for selecting one or more immunotherapeutic preparation having improved properties as a vaccine against a target antigen, said method comprising raising antibodies against a group of candidate preparations and selecting one or more preparations which produces antibodies having higher affinity against the target antigen than does anti-bodies raised against at least one other preparation from the group. More particularly it relates to the need to provide recombinant allergens (Bet V 1) for SIT which have been modified by protein engineering.

Abstract: The properties of a fungal lipolytic enzyme can be altered by substituting amino acid residues corresponding to certain specified amino acid residues in the T. lanuginosus lipase. The altered property may be, e.g., an increased thermostability, an altered pH dependence, or an altered substrate specificity.

Abstract: The present invention provides a method for producing a protein complex comprising the steps of constructing a fusion polynucleotide sequence in frame, the sequence comprising a first gene encoding a protease, and a second gene encoding a protease inhibitor; introducing the sequence into a host cell; cultivating the host cell, wherein the cell expresses the sequence and produces a non-covalently linked complex of the protease and the inhibitor; and recovering the complex.

Abstract: A polypeptide-polymer conjugate is prepared having one or more polymers covalently bound to a polypeptide. The polymer has the general formula; EOXPOY wherein EO is ethylene oxide, PO is propylene oxide, x=1−99%, y=1−99%, x+y=100%, and x and y are in a ratio range of 10:90 to 90:10, more preferably 40:60 to 60:40, or in a 50/50 ratio. The polymer, which can be a block polymer, typically has a molecular weight in a range of 100 to 100,000 daltons, and the polypeptide may contain 1 to 100 polymer molecules. Coupling the polypeptide, in particular enzymes, to the polymer reduces respiratory allergenicity of the polypeptide. Industrial compositions such as detergent compositions, personal care compositions, compositions for processing/treating textiles, and food and feed compositions containing the polypeptide-polymer conjugate have reduced respiratory allergenicity.

Abstract: The present invention relates to polypeptide-polymer conjugates having added and/or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure, a method for preparing polypeptide-polymer conjugates of the invention, the use of said conjugates for reducing the immunogenicity and allergenicity and compositions comprising said conjugate.

Abstract: The properties of a fungal lipolytic enzyme can be altered by substituting amino acid residues corresponding to certain specified amino acid residues in the T. lanuginosus lipase. The altered property may be, e.g., an increased thermostability, an altered pH dependence, or an altered substrate specificity.

Abstract: The present invention relates to a kit for predicting binding of specific antibodies to potential immunogens. The kit comprises antigenic peptide sequences having less than 26 amino acids, said antigenic peptide sequences being capable of binding antibodies specific for structural epitopes contained on potential immunogens. The antigenic peptide sequences are immobilized on a solid support.

Abstract: The present invention relates to polypeptides with reduced immune response including reduced allergenicity having one or more amino acid residues being substituted with other amino acid residues and/or having coupled one or more polymeric molecules in the vicinity of the polypeptides metal binding site, a method for preparing modified polypeptides of the invention, the use of the polypeptide for reducing the immunogenicity and allergenicity and compositions comprising the polypeptide.

Abstract: The present invention relates to a method of producing a transgenic plant expressing a protein having modified immunogenicity as compared to the parent protein, a transgenic plant expressing said protein, which is less immunogenic as compared to the non-transgenic plant.

Abstract: The invention relates to a method for the assessment of the allergenicity or the toxicity of a test compound and for the screening of at least two compounds simultaneously. The invention also relates to a method of characterizing a cell type for the present invention, as well as an assay kit for the high through-put screening of a compound. By contacting a cell culture of at least one cell type of animal origin with the test compound and measuring cytokine responses, the allergenicity of the test compound can be assessed.

Abstract: The present invention relates to polypeptides with reduced immune response including reduced allergenicity having one or more amino acid residues being substituted with other amino acid residues and/or having coupled one or more polymeric molecules in the vicinity of the polypeptides metal binding site, a method for preparing modified polypeptides of the invention, the use of the polypeptide for reducing the immunogenicity and allergenicity and compositions comprising the polypeptide.

Abstract: The present invention is to provide a method to perform assays that efficiently and accurately can screen large numbers of cell populations producing variants of a molecule of interest.

Abstract: The present invention relates to modified polypeptides with reduced respiratory allergenicity having polymeric molecules with a molecular weight from 100 up to 750 Da, coupled covalently to the parent polypeptide having a molecular weight from 5 to 100 kDa. The present invention also relates to industrial compositions comprising modified polypeptide with reduced respiratory allergenicity, skin care products, the use of modified polypeptides for reducing the allergenicity of industrial composition and products and finally a method for reducing the allergenicity of polypeptides.

Abstract: The present invention relates to polypeptide-polymer conjugates having added and/or removed one or more attachment groups for coupling polymeric molecules on the surface of the polypeptide structure, a method for preparing polypeptide-polymer conjugates of the invention, the use of said conjugated for reducing the immunogenicity and allergenicity and compositions comprising said conjugate.